Free Trial

Straumann (OTCMKTS:SAUHY) Shares Gap Down - What's Next?

Straumann logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Straumann (OTCMKTS:SAUHY) gapped down premarket, opening at $10.07 versus the prior close of $10.41, and last traded at $10.49 on light volume (3,566 shares).
  • Analyst sentiment is mixed but cautious: Citigroup and Morgan Stanley have negative ratings (sell/underweight), and the six‑analyst consensus averages to a "Hold" (1 Strong Buy, 1 Buy, 2 Hold, 2 Sell).
  • The stock is trading below both its 50‑day ($11.37) and 200‑day ($11.59) moving averages, indicating continued technical downside pressure.
  • MarketBeat previews top five stocks to own in June.

Straumann Holding AG (OTCMKTS:SAUHY - Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $10.41, but opened at $10.07. Straumann shares last traded at $10.49, with a volume of 3,566 shares.

Analyst Upgrades and Downgrades

SAUHY has been the topic of a number of research reports. Citigroup restated a "sell" rating on shares of Straumann in a research report on Wednesday, January 14th. Morgan Stanley reissued an "underweight" rating on shares of Straumann in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold".

Check Out Our Latest Research Report on Straumann

Straumann Trading Down 0.1%

The firm has a fifty day moving average of $11.37 and a 200-day moving average of $11.59.

About Straumann

(Get Free Report)

Straumann OTCMKTS: SAUHY is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company's core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.

In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Straumann Right Now?

Before you consider Straumann, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Straumann wasn't on the list.

While Straumann currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines